Synapse - Works

Treatment outcomes and prognostic factors with lenalidomide, bortezomib, and dexamethasone (RVd) alone versus RVd plus autologous stem cell transplantation (ASCT) in African American (AA) patients (pts) with newly diagnosed multiple myeloma (NDMM) in the DETERMINATION phase 3 trial

Meeting Abstract

Houde, C. A.; Khan, A.; Jacobus, S. J.; Hassoun, H.; Anderson, L. D. Jr; Merz, L. E.; Zon, R. L.; Efebera, Y.; Buck, T.; Innis-Shelton, R. D.; more...
Blood (2023)

Fulltext@MSK | Save

Outcomes of patients with accelerated/blast-phase MPNs that received allogeneic stem-cell transplant in the current era of myeloid therapies

Meeting Abstract

Patel, A. A.; Yoon, J. J.; Johnston, H.; Davidson, M. B.; Viswabandya, A.; Shallis, R. M.; Chen, E. C.; Burkart, M.; Oh, T. S.; Iyer, S. G.; more...
Blood (2023)

Fulltext@MSK | Save

Pirtobrutinib, a highly selective, non-covalent (reversible) BTK inhibitor in relapsed/refractory follicular lymphoma: Results from the phase 1/2 BRUIN study

Meeting Abstract

Shah, N. N.; Zinzani, P. L.; Wang, M. L.; Nasta, S. D.; Lech-Maranda, E.; Ogawa, Y.; Fakhri, B.; Kuss, B.; Miyashita, K.; Patel, K.; more...
Blood (2023)

Fulltext@MSK | Save

Sustained efficacy and safety with asciminib (ASC) after almost 4 years of median follow-up from ASCEMBL, a phase 3 study of ASC vs bosutinib (BOS) in patients (pts) with chronic myeloid leukemia in chronic phase (CML-CP) after ≥2 prior tyrosine kinase inhibitors (TKIs): An end of study treatment (EOS Tx) update, including results from switch population

Meeting Abstract

Mauro, M.; Minami, Y.; Hochhaus, A.; Lomaia, E.; Voloshin, S.; Turkina, A.; Kim, D. W.; Apperley, J. F.; Cortes, J.; Abdo, A. N. R.; more...
Blood (2023)

Fulltext@MSK | Save